Press Releases
2019
- November 5 Torii has entered into a License Agreement with BioCryst Pharmaceuticals, Inc. for BCX7353 for the prevention of HAE attacks（PDF）
- September 2 JT Transfers the Marketing Approvals of Six Anti-HIV Drugs in Japan to Gilead Sciences K.K.（PDF）
- July 12 Top-line Results of Phase 3 Clinical Studies of JTZ-951 (enarodustat),in Anemic Patients with Chronic Kidney Disease(Comparative Study) in Japan（PDF）
- July 9 Top-line Results of Phase 3 Clinical Study of Riona®, (ferric citrate hydrate), in Adult Patients with Iron Deficiency Anemia (Comparative Study) in Japan（PDF）
- June 17 Results of Voluntary Retirement Program（PDF）
- May 30 Implementation of Organizational Reform（PDF）
- April 25 Top-line Results of JTE-052 Ointment, JAK inhibitor, Phase 3 Clinical Study in Pediatric Patients with Atopic Dermatitis (Comparative Study) in Japan（PDF）
- March 1 A Presentation on the Phase 3 Clinical Study (Comparative Study) of JTE-052 Ointment, JAK Inhibitor, at the 2019 AAD annual meeting（PDF）
- February 6 Torii has announced the Medium-Term Management Plan 2021（PDF）
- February 6 TRANSFER OF RIGHTS TO protease inhibitor FUTHAN® for injection（PDF）
- January 31 JT Files New Drug Application of JTE-052 Ointment, JAK inhibitor, for the Treatment of Atopic Dermatitis in Japan（PDF）
2018
- December 14 The date for terminating the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs in Japan has been set（PDF）
- November 29 Torii has agreed with JT to terminate the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs in Japan（PDF）
- August 27 JT Signs a Letter of Intent to Initiate Discussion to Terminate Agreements on Exclusive Rights to Develop, Commercialize and Market of Six Anti-HIV Drugs in Japan（PDF）
- June 28 JT and Torii Discontinue Development of NK-1 Receptor Antagonist (JTS-661) and Terminate Exclusive License Agreement with Menlo Therapeutics（PDF）
- May 24 Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- April 18 Price Listing on the NHI Reimbursement List and Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- February 16 Torii receives approval for additional dosage and administration for pediatric indication for MITICURE® House Dust Mite Sublingual Tablets, an Allergen Immunotherapy Tablet for House Dust Mite Allergy（PDF）
- January 12 Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan（PDF）
2017
- October 26 JT and Torii Sign Exclusive License Agreement for Development and Commercialization of HIF-PH inhibitor in Japan（PDF）
- October 5 Torii announces Postponement of Price Listing on the NHI Reimbursement List for “CEDARCURE ® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- September 27 New Drug Application Approval of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- September 22 Toray Receives Japanese Approval for an Additional Indication of Pruritus Treatment REMITCH® CAPSULES 2.5µg and REMITCH® OD Tablets 2.5μg（PDF）
- May 31 Toray’s Pruritus Treatment REMITCH® OD Tablets 2.5 μg to Be Introduced in Japan（PDF）
- March 30 Toray Receives Japanese Approval for an Additional Formulation of Pruritus Treatment REMITCH® OD TABLETS 2.5µg（PDF）
- March 24 Torii files an additional pediatric indication for TO-203 (MITICURE® House Dust Mite Sublingual Tablets), an Allergen Immunotherapy Tablet for House Dust Mite Allergy（PDF）
Older press releases can be found in the Back Number.